The estimated Net Worth of Richard Paul Bryce is at least $2.39 Milione dollars as of 5 April 2021. Richard Bryce owns over 426 units of Puma Biotechnology Inc stock worth over $304,155 and over the last 12 years he sold PBYI stock worth over $752,520. In addition, he makes $1,331,140 as Chief Medical and Scientific Officer at Puma Biotechnology Inc.
Richard has made over 39 trades of the Puma Biotechnology Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 426 units of PBYI stock worth $4,175 on 5 April 2021.
The largest trade he's ever made was exercising 15,000 units of Puma Biotechnology Inc stock on 29 September 2017 worth over $169,500. On average, Richard trades about 1,210 units every 49 days since 2012. As of 5 April 2021 he still owns at least 121,662 units of Puma Biotechnology Inc stock.
You can see the complete history of Richard Bryce stock trades at the bottom of the page.
Dr. Richard Paul Bryce serves as Chief Medical and Scientific Officer of the Company. Dr. Bryce has served as our Chief Medical and Scientific Officer since August 2017. From June 2012 until August 2017, Dr. Bryce served as our Senior Vice President, Clinical Research and Development. Dr. Bryce previously served as Senior Medical Director for Onyx Pharmaceuticals, a biopharmaceutical company, from September 2008 to June 2012, where he oversaw the Phase III clinical trial program of carfilzomib for the treatment of multiple myeloma and the Phase II clinical trial program of sorafenib for the treatment of breast and colorectal cancers. From August 2007 to August 2008, Dr. Bryce served as Senior Medical Director for ICON Clinical Research, a clinical research organization, where he was responsible for developing and evaluating oncology protocols, medical monitoring, and overseeing drug safety management activities in connection with the clinical trials of oncology drugs. From May 2005 until July 2007, he served as Executive Vice President of Medical Affairs at Ergomed Clinical Research, a clinical research organization, where he worked to establish the company’s U.S. operations, had overall responsibility for the global Phase I unit activities, drug safety, medical writing and regulatory affairs, and oversaw the company’s provision of consulting services to various oncology-focused biotechnology companies. From April 2003 to May 2005, Dr. Bryce served as International Medical Leader at Roche, where he oversaw the global Phase IV clinical trial program of Xeloda® (capecitabine) for the treatment of breast cancer. Dr. Bryce holds a BSc in Medical Sciences and his primary medical degree (MBChB) from the University of Edinburgh, Scotland. He also holds post-graduate diplomas in Obstetrics and Gynaecology from the Royal College of Obstetricians and Gynaecologists of London and in Child Health and Pharmaceutical Medicine from the Royal College of Physicians of the United Kingdom. He is a member of the Royal College of G
As the Chief Medical and Scientific Officer of Puma Biotechnology Inc, the total compensation of Richard Bryce at Puma Biotechnology Inc is $1,331,140. There are 6 executives at Puma Biotechnology Inc getting paid more, with Alan H. Auerbach having the highest compensation of $5,693,423.
Richard Bryce is 62, he's been the Chief Medical and Scientific Officer of Puma Biotechnology Inc since 2017. There are 3 older and 11 younger executives at Puma Biotechnology Inc. The oldest executive at Puma Biotechnology Inc is Jay Moyes, 66, who is the Lead Independent Director.
Richard's mailing address filed with the SEC is 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.
Over the last 13 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo e Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
Puma Biotechnology Inc executives and other stock owners filed with the SEC include: